All Posts

A long time ago - when I was a 20‑year‑old Materials Engineering undergrad on a country road in rural Pennsylvania - I learned the most important lesson of my process‑engineering life. I was working at Pittsburgh Corning’s glass block factory, home of those unmistakably 1970s basement‑window blocks. I had zero real engineering experience, just enthusiasm and the belief I could change the world. Glass Science is the youngest of the material sciences. Metallurgy degrees date ba

The Chinese pharmaceutical industry is rapidly transforming from a producer of lower‑cost generics to an innovator of new drugs for increasingly complex treatments. The shift has been so significant that nearly half of the drugs entering human trials in the first half of 2025 originated from Chinese biopharma companies. This surge in innovation—combined with a dramatic increase in global licensing deals—is positioning China to become a pivotal contributor not only in pharmace

In a world of ever‑shrinking resources, organizations often respond with massive, top‑down initiatives designed to “fix everything at once.” These programs look impressive on paper—big budgets, big teams, big promises—but they frequently suffocate under their own weight. As timelines slip and scope gets cut, the effort collapses into a familiar pattern: more burden, little benefit, and a demoralized workforce left holding the bag. It’s a painful descent into subpar results, i

Overly conservative risk files don’t protect patients — they distort reality, undermine engineering judgment, and create regulatory and post‑market chaos.

This Table has Nothing to do with the Actual Requirements for Accepting Risk ISO 14971:2019 defines four criteria for determining whether residual risk is acceptable: Were risk controls implemented in the required priority order? (Inherently safe by design → protective measures → information for safety) (ISO 14971:2019 A.2.7.1) Was the effectiveness of those controls verified? (A.2.7.2) Has risk been reduced as far as practicable? (A.2.7.3) Does the benefit outweigh the resid

Post‑market surveillance isn’t a checkbox exercise; its value comes from detecting real signals, distinguishing systemic issues, and driving continuous improvement.

ISO 14971 strengthens hazard identification, use analysis, and benefit–risk evaluation, but much of its value is lost when organizations treat risk management as a compliance task. Late analyses, underused tools, and poor integration into daily operations limit effectiveness. Embedding risk‑based thinking into design, manufacturing, and decision‑making unlocks its full impact.

In pharma and med‑tech, inspections aren’t just compliance events—they’re strategic inflection points. One unexpected observation can stall approvals, drain resources, and shake investor and regulator confidence. The real risk isn’t the finding. It’s being surprised by it.

The legacy “three batches” may no longer sail through regulatory review The long‑standing convention of running three Process Validation batches has never been grounded in statistical science. Regulations have always placed the burden on manufacturers to justify the number of batches, with the true standard being: demonstrate homogeneity within a batch and consistency between batches. Despite this, the three‑batch approach persisted for decades because it rarely triggered reg

If process validation feels like a box-checking exercise in your organization, you’re not alone. Too often, validation is run as a disconnected set of tasks—leaving gaps that show up later as process deviations, nonconforming product, and a lack of confidence in day-to-day output. See what process validation is really meant to achieve—and how a mindset shift can turn it into a practical, value-added system that improves predictability and quality, rather than a last-minute co